Literature DB >> 2964482

Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes.

N K Damle1, L V Doyle, L S Grosmaire, J A Ledbetter.   

Abstract

Molecule CD28 (Tp44) is expressed on the surface of majority of human T cells and has been implicated to play an active role in the regulation of T cell growth. The present study examines the effect of antibody binding to the CD28 molecule during T cell activation. Anti-CD28 but not isotype-matched anti-CD5 mAb consistently augmented anti-CD3-induced and IL-2-induced T cell proliferation and subsequent release of soluble CD25 molecule. When added together, mAb anti-CD28 and anti-CD5 acted synergistically to cause 2- to 7-fold enhancement of T cell activation induced by anti-CD3 mAb or IL-2 with no effect on the development of non-MHC-restricted IL-2-activated killer T cells. In contrast, alloantigen-induced T cell proliferation, soluble CD25 release, and the subsequent development of CTL were all inhibited by anti-CD28 mAb. Moreover, alloantigen-induced proliferative response of both CD4+ and CD8+ T cells was inhibited by anti-CD28 without affecting the cytolytic effect of CTL. Because valency of anti-CD28 binding has been implicated as an important factor in signal transduction, this was explored in the allogeneic MLR by using Fab and F(ab')2 fragments of anti-CD28 mAb and anti-mouse kappa mAb. The inhibitory effect of anti-CD28 mAb in the MLR was reversed by cross-linking of anti-CD28 mAb with anti-mouse kappa mAb. In addition, cross-linking of the CD28 molecule on alloactivated T lymphoblasts but not that on resting T cells with anti-CD28 and anti-mouse kappa induced their proliferation in the absence of the priming alloantigen. These results indicate that stimulatory or inhibitory signals delivered through the CD28 molecule are determined by the degree of cross-linking of this molecule. In addition, these results also suggest that Ag-induced CD3-TCR-mediated T cell responses are more dependent on signals delivered through the CD28 molecule than those induced with anti-CD3, and thus these results have implications for potential use of anti-CD28 in sustained propagation of Ag-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964482

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.

Authors:  M Azuma; M Cayabyab; D Buck; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

Review 2.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

3.  B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

Authors:  C D Gimmi; G J Freeman; J G Gribben; K Sugita; A S Freedman; C Morimoto; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

4.  Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice.

Authors:  G A Holländer; E Castigli; R Kulbacki; M Su; S J Burakoff; J C Gutierrez-Ramos; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.

Authors:  Alfreda D Nelson; Michele M Hoffmann; Christopher A Parks; Surendra Dasari; Adam G Schrum; Diana Gil
Journal:  J Biol Chem       Date:  2012-10-29       Impact factor: 5.157

6.  CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism.

Authors:  Christine M Deppong; Amit Parulekar; Jonathan S Boomer; Traci L Bricker; Jonathan M Green
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 7.  Immunogenomics: using genomics to personalize cancer immunotherapy.

Authors:  Rance C Siniard; Shuko Harada
Journal:  Virchows Arch       Date:  2017-05-20       Impact factor: 4.064

Review 8.  Co-stimulation Blockade Plus T-Cell Depletion in Transplant Patients: Towards a Steroid- and Calcineurin Inhibitor-Free Future?

Authors:  Florence Herr; Melanie Brunel; Nathalie Roders; Antoine Durrbach
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

Review 9.  At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.

Authors:  Anthony F O Daniyan; Renier J Brentjens
Journal:  J Leukoc Biol       Date:  2016-10-27       Impact factor: 4.962

10.  B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation.

Authors:  D N Hart; G C Starling; V L Calder; N S Fernando
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.